This review provides a comprehensive framework for the diagnostic approach and management of Huntington’s disease (HD) tailored to the Korean population. Key topics include genetic counseling, predictive testing, and reproductive options like preimplantation genetic testing. Strategies for assessing disease progression in premanifest HD through laboratory investigations, biofluid, and imaging biomarkers are highlighted. Special considerations for juvenile and late-onset HD, along with associated comorbidities like diabetes mellitus, hypertension, and cardiovascular abnormalities, are discussed. The guide emphasizes personalized symptom management, including pharmacotherapy, physical therapy, and nutritional support, while exploring emerging disease-modifying treatments. A multidisciplinary care model is advocated to improve outcomes for HD patients and caregivers in Korea.
Objective This study aims to objectively evaluate turning gait parameters in Parkinson’s disease (PD) patients using 2D-RGB video-based analysis and explore their relationships with imbalance.
Methods We prospectively enrolled PD patients for clinical assessment, balance analysis and gait with 180º turning. Spatiotemporal gait parameters during turning were derived using video-based analysis and correlated with modified Hoehn and Yahr (mHY) stages and center of pressure (COP) oscillations.
Results A total of 64 PD patients were enrolled. The PD patients with higher mHY stages (≥2.5) had significantly longer turning times, greater numbers of steps, wider step bases and less variability in step length during turns. COP oscillations were positively correlated with the mean turning time on both the anterior-posterior and right-left axes.
Conclusion Spatiotemporal gait parameter during turning, derived from video-based gait analysis, may represent apromising biomarker for monitoring postural instability in PD patients.
Citations
Citations to this article as recorded by
Uncovering the Kinematic Signature of Freezing of Gait in Parkinson’s Disease Through Wearable Inertial Sensors Francesco Castelli Gattinara Di Zubiena, Alessandro Zampogna, Martina Patera, Giovanni Cusolito, Ludovica Apa, Ilaria Mileti, Antonio Cannuli, Antonio Suppa, Marco Paoloni, Zaccaria Del Prete, Eduardo Palermo Sensors.2025; 25(16): 5054. CrossRef
Gait Patterns and Balance Impairment in Parkinson’s Disease With Correlation to Disease Severity Danyeong Kim, Da-Eun Jeong, Hyunkyung Yi, Min Ju Kang Dementia and Neurocognitive Disorders.2025; 24(4): 259. CrossRef
Clinical and neuroimaging correlates of disease related gait patterns in patients with multiple system atrophy cerebellar type Seungmin Lee, Minchul Kim, Kyu Sung Choi, Chanhee Jeong, Ri Yu, Jee-Young Lee, Jung Hwan Shin, Han-Joon Kim, Beomseok Jeon Scientific Reports.2025;[Epub] CrossRef
A Practical Guide for Diagnostic Investigations and Special Considerations in Patients With Huntington’s Disease in Korea Jangsup Moon, Eungseok Oh, Minkyeong Kim, Ryul Kim, Dallah Yoo, Chaewon Shin, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon Journal of Movement Disorders.2025; 18(1): 17. CrossRef
Validation of the Korean Version of the Huntington’s Disease Quality of Life Battery for Carers Hee Jin Chang, Eungseok Oh, Won Tae Yoon, Chan Young Lee, Kyum-Yil Kwon, Yun Su Hwang, Chaewon Shin, Jee-Young Lee Journal of Movement Disorders.2025; 18(2): 160. CrossRef
Huntington Disease and Chorea Kathryn P. L. Moore Continuum.2025; 31(4): 1066. CrossRef
AI-Enhanced Transcriptomic Discovery of Druggable Targets and Repurposed Therapies for Huntington’s Disease Rodrigo Pinheiro Araldi, João Rafael Dias Pinto, Irina Kerkis Brain Sciences.2025; 15(8): 865. CrossRef
Chan Young Lee, Chaewon Shin, Yun Su Hwang, Eungseok Oh, Manho Kim, Hyun Sook Kim, Sun Ju Chung, Young Hee Sung, Won Tae Yoon, Jin Whan Cho, Jae-Hyeok Lee, Han-Joon Kim, Hee Jin Chang, Beomseok Jeon, Kyung Ah Woo, Seong-Beom Koh, Kyum-Yil Kwon, Jangsup Moon, Young Eun Kim, Jee-Young Lee
J Mov Disord. 2024;17(1):30-37. Published online September 11, 2023
Objective This is the first prospective cohort study of Huntington’s disease (HD) in Korea. This study aimed to investigate the caregiver burden in relation to the characteristics of patients and caregivers.
Methods From August 2020 to February 2022, we enrolled patients with HD from 13 university hospitals in Korea. We used the 12-item Zarit Burden Interview (ZBI-12) to evaluate the caregiver burden. We evaluated the clinical associations of the ZBI-12 scores by linear regression analysis and investigated the differences between the low- and high-burden groups.
Results Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study. The average age at onset of motor symptoms was 49.3 ± 12.3 years, with an average cytosine-adenine-guanine (CAG)n of 42.9 ± 4.0 (38–65). The median ZBI-12 score among our caregivers was 17.6 ± 14.2. A higher caregiver burden was associated with a more severe Shoulson–Fahn stage (p = 0.038) of the patients. A higher ZBI-12 score was also associated with lower independence scale (B = -0.154, p = 0.006) and functional capacity (B = -1.082, p = 0.002) scores of patients. The caregiving duration was longer in the high- than in the low-burden group. Caregivers’ demographics, blood relation, and marital and social status did not affect the burden significantly.
Conclusion HD patients’ neurological status exerts an enormous impact on the caregiver burden regardless of the demographic or social status of the caregiver. This study emphasizes the need to establish an optimal support system for families dealing with HD in Korea. A future longitudinal analysis could help us understand how disease progression aggravates the caregiver burden throughout the entire disease course.
Citations
Citations to this article as recorded by
Attitude toward physical activity among Asian American family caregivers of persons living with dementia JiWon Choi, Van Park, Andrew Jung, Janice Tsoh Geriatric Nursing.2025; 62: 276. CrossRef
Non-Pharmacological Interventions for Caregivers of People with Motor Neurone Disease: A Scoping Review of Psychosocial Outcomes Chidera Okoh, Leighanne Mayall, Selina M. Makin, Cliff Chen, Nicolò Zarotti Brain Sciences.2025; 15(2): 112. CrossRef
A Practical Guide for Diagnostic Investigations and Special Considerations in Patients With Huntington’s Disease in Korea Jangsup Moon, Eungseok Oh, Minkyeong Kim, Ryul Kim, Dallah Yoo, Chaewon Shin, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon Journal of Movement Disorders.2025; 18(1): 17. CrossRef
Validation of the Korean Version of the Huntington’s Disease Quality of Life Battery for Carers Hee Jin Chang, Eungseok Oh, Won Tae Yoon, Chan Young Lee, Kyum-Yil Kwon, Yun Su Hwang, Chaewon Shin, Jee-Young Lee Journal of Movement Disorders.2025; 18(2): 160. CrossRef
Mapping the landscape of caregiver burden in Huntington's Disease: Current evidence and future directions Katerina Poprelka, Theodoros Fasilis, Panayiotis Patrikelis, Evniki Ntinopoulou, Anastasia Verentzioti, Maria Stefanatou, Athanasia Alexoudi, Lampis C Stavrinou, Stefanos Korfias, Stylianos Gatzonis Journal of Huntington's Disease.2025; 14(4): 304. CrossRef
Quality of life and care burden of people living with amyotrophic lateral sclerosis who need home-based medical care in Korea and their family caregivers Shin Hye Yoo, Belong Cho, Kyae Hyung Kim, In Young Hwang, Woohyeon Cho, Seok-Jin Choi, Jung-Joon Sung, Sun Young Lee Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2025; : 1. CrossRef
A Practical Guide for Clinical Approach to Patients With Huntington’s Disease in Korea Chaewon Shin, Ryul Kim, Dallah Yoo, Eungseok Oh, Jangsup Moon, Minkyeong Kim, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon Journal of Movement Disorders.2024; 17(2): 138. CrossRef
Clinical case studies and reporting are important to the discovery of new disorders and the advancement of medical sciences. Both clinicians and basic scientists play equally important roles leading to treatment discoveries for both cures and symptoms. In the field of movement disorders, exceptional observation of patients from clinicians is imperative, not just for phenomenology but also for the variable occurrences of these disorders, along with other signs and symptoms, throughout the day and the disease course. The Movement Disorders in Asia Task Force (TF) was formed to help enhance and promote collaboration and research on movement disorders within the region. As a start, the TF has reviewed the original studies of the movement disorders that were preliminarily described in the region. These include nine disorders that were first described in Asia: Segawa disease, PARK-Parkin, X-linked dystonia-parkinsonism, dentatorubral-pallidoluysian atrophy, Woodhouse-Sakati syndrome, benign adult familial myoclonic epilepsy, Kufor-Rakeb disease, tremulous dystonia associated with mutation of the calmodulin-binding transcription activator 2 gene, and paroxysmal kinesigenic dyskinesia. We hope that the information provided will honor the original researchers and help us learn and understand how earlier neurologists and basic scientists together discovered new disorders and made advances in the field, which impact us all to this day.
Citations
Citations to this article as recorded by
Genetic heterogeneity of early onset Parkinson disease: The dilemma of clinico-genetic correlation Roopa Rajan, Vikram V. Holla, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal Parkinsonism & Related Disorders.2024; 129: 107146. CrossRef
Nongenetic movement disorders are common throughout the world. The movement disorders encountered may vary depending on the prevalence of certain disorders across various geographical regions. In this paper, we review historical and more common nongenetic movement disorders in Asia. The underlying causes of these movement disorders are diverse and include, among others, nutritional deficiencies, toxic and metabolic causes, and cultural Latah syndrome, contributed by geographical, economic, and cultural differences across Asia. The industrial revolution in Japan and Korea has led to diseases related to environmental toxin poisoning, such as Minamata disease and β-fluoroethyl acetate-associated cerebellar degeneration, respectively, while religious dietary restriction in the Indian subcontinent has led to infantile tremor syndrome related to vitamin B12 deficiency. In this review, we identify the salient features and key contributing factors in the development of these disorders.
Citations
Citations to this article as recorded by
Diabetic striatopathy and other acute onset de novo movement disorders in hyperglycemia Subhankar Chatterjee, Ritwik Ghosh, Payel Biswas, Shambaditya Das, Samya Sengupta, Souvik Dubey, Biman Kanti Ray, Alak Pandit, Julián Benito-León, Rana Bhattacharjee Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(3): 102997. CrossRef
Tremors in Infantile Tremor Syndrome Mimicking Epilepsia Partialis Continua Tonyot Gailson, Pradeep Kumar Gunasekaran, Arushi Gahlot Saini, Chaithanya Reddy Journal of Movement Disorders.2024; 17(3): 351. CrossRef
A review of treatment methods for movement disorders Mahdi Khezri, Shakiba Afsar Behavioural Brain Research.2026; 500: 115979. CrossRef
Amantadine: a first option for symptomatic relief in young-onset Parkinson's disease? Hyeyoung Park, Bastiaan R. Bloem, Beomseok Jeon Parkinsonism & Related Disorders.2026; 144: 108215. CrossRef
Altered Mental Status Due to Amantadine Withdrawal: A Case Report Nicole J. Asal, Elisa Piraino, Cristina Hamacher, Husam Abu Nejim Reports.2026; 9(1): 85. CrossRef
Approaches for treating cardiovascular symptoms in Parkinson’s disease Wolfgang H. Jost, Jiri Koschel Therapeutic Advances in Neurological Disorders.2025;[Epub] CrossRef
The Effect of Dopaminergic Therapies in Parkinson’s Disease on Non-Motor Symptoms Monika Jampolska, Katarzyna Kaczyńska International Journal of Molecular Sciences.2025; 26(24): 11996. CrossRef
Efficacy of telerehabilitation with digital and robotic tools for the continuity of care of people with chronic neurological disorders: The TELENEURO@REHAB protocol for a randomized controlled trial Federica Rossetto, Fabiola Giovanna Mestanza Mattos, Elisa Gervasoni, Marco Germanotta, Arianna Pavan, Davide Cattaneo, Irene Aprile, Francesca Baglio DIGITAL HEALTH.2024;[Epub] CrossRef
Objective This study aimed to evaluate whether a larger tissue volume increases the sensitivity of detecting alpha-synuclein (AS) pathology in the gastrointestinal (GI) tract.
Methods Nine patients with Parkinson’s disease (PD) or idiopathic rapid eye movement sleep disorder (iRBD) who underwent GI operation and had full-depth intestinal blocks were included. All patients were selected from our previous study population. A total of 10 slides (5 serial sections from the proximal and distal blocks) per patient were analyzed.
Results In previous studies, pathologic evaluation revealed phosphorylated AS (+) in 5/9 patients (55.6%) and in 1/5 controls (20.0%); in this extensive examination, this increased to 8/9 patients (88.9%) but remained the same in controls (20.0%). The severity and distribution of positive findings were similar between patients with iRBD and PD.
Conclusion Examining a large tissue volume increased the sensitivity of detecting AS accumulation in the GI tract.
Citations
Citations to this article as recorded by
Gut-initiated alpha synuclein fibrils drive parkinsonism phenotypes: temporal mapping of REM sleep behavior disorder-like and other non-motor symptoms Daniel Dautan, Wojciech Paslawski, Sergio G. Montejo, Daniel C. Doyon, Valentina I. Brioschi, Roberta Marongiu, Michael G. Kaplitt, Rong Chen, Valina L. Dawson, Xiaoqun Zhang, Ted M. Dawson, Per Svenningsson Translational Neurodegeneration.2026;[Epub] CrossRef
Tracking prodromal Parkinson’s disease: a five-year follow-up of the PARCAS cohort Kristina Kulcsarova, Petronela Christova, Martina Bekeova, Sona Muranska, Sona Mrazova, Zuzana Mrazova, Barbora Zecova, Filip Faglic, Simona Suvakova, Norbert Lesko, Laura Gombosova, Zuzana Gdovinova, Matej Skorvanek Frontiers in Neurology.2025;[Epub] CrossRef
Symmetric and Profound Monoaminergic Degeneration in Parkinson’s Disease with Premotor REM Sleep Behavior Disorder Kyung Ah Woo, Han-Joon Kim, Jung Hwan Shin, Kangyoung Cho, Hongyoon Choi, Beomseok Jeon Journal of Parkinson’s Disease.2024; 14(4): 823. CrossRef
Objective To investigate the long-term clinical outcomes of pallidal deep brain stimulation (GPi-DBS) in patients with pantothenate kinase-associated neurodegeneration (PKAN).
Methods We reviewed the records of patients with genetically confirmed PKAN who received bilateral GPi-DBS for refractory dystonia and were clinically followed up for at least 2 years postoperatively at two centers in Korea. Pre- and postoperative Burke– Fahn–Marsden Dystonia Rating Scale motor subscale (BFMDRS-M) scores, disability subscale (BFMDRS-D) scores, and qualitative clinical information were prospectively collected. Descriptive analysis was performed for BFMDRS-M scores, BFMDRSD scores, and the orofacial, axial, and limb subscores of the BFMDRS-M at 6–12, 24–36, and 60–72 months postoperatively.
Results Five classic-type, four atypical-type, and one unknown-type PKAN cases were identified. The mean preoperative BFMDRS-M score was 92.1 for the classic type and 38.5 for the atypical or unknown type, with a mean BFMDRS follow-up of 50.7 months and a clinical follow-up of 69.0 months. The mean improvements in BFMDRS-M score were 11.3%, 41.3%, and 30.5% at 6–12, 24–36, and 60–72 months, respectively. In four patients with full regular evaluations until 60–72 months, improvements in the orofacial, axial, and limb subscores persisted, but the disability scores worsened from 24–36 months post-operation compared to the baseline, mainly owing to the aggravation of eating and feeding disabilities.
Conclusion The benefits of GPi-DBS on dystonia may persist for more than 5 years in PKAN. The effects on patients’ subjective disability may have a shorter duration despite improvements in dystonia owing to the complex manifestations of PKAN.
Citations
Citations to this article as recorded by
Imaging Findings of Intracerebral Infection after Deep Brain Stimulation: Pediatric Case Series and Literature Review Andrew Z. Yang, Alexandre Boutet, Vivek Pai, Michael J. Colditz, Artur Vetkas, Brendan Santyr, Nardin Samuel, Jurgen Germann, Sara Breitbart, Lior Elkam, Birgit Ertl‐Wagner, Alfonso Fasano, Andres M. Lozano, George M Ibrahim, Carolina Gorodetsky Movement Disorders Clinical Practice.2025; 12(2): 242. CrossRef
Hallerworden – Spatz DISEASE. Clinical case L. B. Novikova, K. M. Ziultsle, A. P. Akopian Medical alphabet.2025; (33): 34. CrossRef
Pantothenate kinase-associated neurodegeneration L. B. Novikova, A. P. Akopyan, K. M. Ziultsle Russian neurological journal.2025; 30(4): 44. CrossRef
Deep Brain Stimulation for Refractory Status Dystonicus in Children: Multicenter Case Series and Systematic Review Lindsey M. Vogt, Han Yan, Brendan Santyr, Sara Breitbart, Melanie Anderson, Jürgen Germann, Karlo J. Lizarraga, Angela L. Hewitt, Alfonso Fasano, George M. Ibrahim, Carolina Gorodetsky Annals of Neurology.2024; 95(1): 156. CrossRef
Illustration of the long-term efficacy of pallidal deep brain stimulation in a patient with PKAN dystonia Luigi M. Romito, Fabiana Colucci, Giovanna Zorzi, Barbara Garavaglia, Ahmet Kaymak, Alberto Mazzoni, Celeste Panteghini, Nico Golfrè Andreasi, Sara Rinaldo, Vincenzo Levi, Miryam Carecchio, Roberto Eleopra Parkinsonism & Related Disorders.2024; 123: 106977. CrossRef
Case of Hallervorden–Spatz Syndrome: A Tale of Twin Sisters Naveen Reddy, Jitender Sharma, Anmol Sharma Neurology India.2024; 72(2): 411. CrossRef
Patient Selection for Deep Brain Stimulation for Pantothenate Kinase-Associated Neurodegeneration Jason L. Chan, Ashley E. Rawls, Joshua K. Wong, Penelope Hogarth, Justin D. Hilliard, Michael S. Okun Tremor and Other Hyperkinetic Movements.2024;[Epub] CrossRef
Surgical treatment of movement disorders in neurometabolic conditions Alonso Zea Vera, Andrea L. Gropman Frontiers in Neurology.2023;[Epub] CrossRef
Objective Putaminal iron deposition is an important feature that helps differentiate multiple system atrophy with predominant parkinsonism (MSA-p) from Parkinson’s disease (PD). Most previous studies used visual inspection or quantitative methods with manual manipulation to perform this differentiation. We investigated the value of a new semiautomated diagnostic algorithm using 3T-MR susceptibility-weighted imaging for MSA-p.
Methods This study included 26 MSA-p, 68 PD, and 41 normal control (NC) subjects. The algorithm was developed in 2 steps: 1) determine the image containing the remarkable putaminal margin and 2) calculate the phase-shift values, which reflect the iron concentration. The next step was to identify the best differentiating conditions among several combinations. The highest phaseshift value of each subject was used to assess the most effective diagnostic set.
Results The raw phase-shift values were present along the lateral margin of the putamen in each group. It demonstrates an anterior- to-posterior gradient that was identified most frequently in MSA-p. The average of anterior 5 phase shift values were used for normalization. The highest area under the receiver operating characteristic curve (0.874, 80.8% sensitivity, and 86.7% specificity) of MSA-p versus PD was obtained under the combination of 3 or 4 vertical pixels and one dominant side when the normalization methods were applied. In the subanalysis for the MSA-p patients with a longer disease duration, the performance of the algorithm improved.
Conclusion This algorithm detected the putaminal lateral margin well, provided insight into the iron distribution of the putaminal rim of MSA-p, and demonstrated good performance in differentiating MSA-p from PD.
Citations
Citations to this article as recorded by
Ocular Vestibular-Evoked Myogenic Potential Assists in the Differentiation of Multiple System Atrophy From Parkinson’s Disease Keun-Tae Kim, Kyoungwon Baik, Sun-Uk Lee, Euyhyun Park, Chan-Nyoung Lee, Tonghoon Woo, Yukang Kim, Seoui Kwag, Hyunsoh Park, Ji-Soo Kim Journal of Movement Disorders.2024; 17(4): 398. CrossRef
Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson’s Disease Ji Su Hwang, Seok Gi Kim, Nimisha Pradeep George, Minjun Kwon, Yong Eun Jang, Sang Seop Lee, Gwang Lee International Journal of Molecular Sciences.2024; 25(24): 13260. CrossRef
Objective Deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson’s disease (PD) patients does not halt disease progression, as these patients will progress and develop disabling non-levodopa responsive symptoms. These features may act as milestones that represent the overall functionality of patients after DBS. The objective of this study was to investigate the development of clinical milestones in advanced PD patients who underwent bilateral STN-DBS.
Methods The study evaluated PD patients who underwent STN-DBS at baseline up to their last follow-up using the Unified Parkinson’s Disease Rating Scale and Hoehn and Yahr scale. The symptoms of hallucinations, dysarthria, dysphagia, frequent falls, difficulty walking, cognitive impairment and the loss of autonomy were chosen as the clinical milestones.
Results A total of 106 patients with a mean age of 47.21 ± 10.52 years at disease onset, a mean age of 58.72 ± 8.74 years at surgery and a mean disease duration of 11.51 ± 4.4 years before surgery were included. Initial improvement of motor symptoms was seen after the surgery with the appearance of clinical milestones over time. Using the moderately disabling criteria, 81 patients (76.41%) developed at least one clinical milestone, while 48 patients (45.28%) developed a milestone when using the severely disabling criteria.
Conclusion STN-DBS has a limited effect on axial and nonmotor symptoms of the PD patients, in contrast to the effect on motor symptoms. These symptoms may serve as clinical milestones that can convey the status of PD patients and its impact on the patients and their caregivers. Therefore, advanced PD patients, even those treated with bilateral STN-DBS, will still require assistance and cannot live independently in the long run.
Citations
Citations to this article as recorded by
Survival after Subthalamic Deep Brain Stimulation for Parkinson's Disease: 25‐Year Experience from a Single Center Sayooja Sachithanandan, Athul Sreelatha Sanjeev, Jissa Vinoda Thulaseedharan, Krishnakumar Kesavapisharady, Divya Kalikavil Puthanveedu, Asish Vijayaraghavan, Gangadhara Sarma, Syam Krishnan, Asha Kishore Movement Disorders Clinical Practice.2025;[Epub] CrossRef
Unveiling the Impact of Outpatient Physiotherapy on Specific Motor Symptoms in Parkinson’s Disease: A Prospective Cohort Study Yuta Terasawa, Koki Ikuno, Shintaro Fujii, Yuki Nishi, Emi Tanizawa, Sachio Nabeshima, Yohei Okada Brain & Neurorehabilitation.2023;[Epub] CrossRef
Objective This study aims to develop an automated and objective tool to evaluate postural abnormalities in Parkinson’s disease (PD) patients.
Methods We applied a deep learning-based pose-estimation algorithm to lateral photos of prospectively enrolled PD patients (n = 28). We automatically measured the anterior flexion angle (AFA) and dropped head angle (DHA), which were validated with conventional manual labeling methods.
Results The automatically measured DHA and AFA were in excellent agreement with manual labeling methods (intraclass correlation coefficient > 0.95) with mean bias equal to or less than 3 degrees.
Conclusion The deep learning-based pose-estimation algorithm objectively measured postural abnormalities in PD patients.
Citations
Citations to this article as recorded by
Research Progress of Camptocormia in Parkinson Disease Yilin Lu, Xiang Zhang, Junyu Li, Weishi Li, Miao Yu Clinical Spine Surgery.2025; 38(2): 39. CrossRef
Spatiotemporal Gait Parameters During Turning and Imbalance in Parkinson’s Disease: Video-Based Analysis From a Single Camera HoYoung Jeon, Jung Hwan Shin, Ri Yu, Min Kyung Kang, Seungmin Lee, Seoyeon Kim, Bora Jin, Kyung Ah Woo, Han-Joon Kim, Beomseok Jeon Journal of Movement Disorders.2025; 18(1): 87. CrossRef
Waveform‐Based Analysis of Head Tremor Using a Marker‐Less Tracking Algorithm with 2D‐Video: Evaluation of Sinusoidality and Rhythmicity Jung Hwan Shin, Seungmin Lee, Kyung Ah Woo, Hyder A. Jinnah, Aasef Shaikh, Mark Hallett, Sanjay Pandey, Rick C. Helmich, Marie Vidailhet, Victor Fung, Alfonso Fasano, Han‐Joon Kim, Beomseok Jeon Movement Disorders.2025; 40(11): 2344. CrossRef
Camptocormia in Parkinson’s disease: state of the art and future directions Valeria Sajin, Mark Goodall, Antonella Macerollo Journal of Neurology.2025;[Epub] CrossRef
AI Video Analysis in Parkinson’s Disease: A Systematic Review of the Most Accurate Computer Vision Tools for Diagnosis, Symptom Monitoring, and Therapy Management Lazzaro di Biase, Pasquale Maria Pecoraro, Francesco Bugamelli Sensors.2025; 25(20): 6373. CrossRef
RecovGait: Occluded Parkinson’s Disease Gait Reconstruction Using Unscented Tracking with Gated Initialization Technique Chiau Wen Yeong, Tee Connie, Thian Song Ong, Nor Izzati Saedon, Ahmad Al-Khatib, Mahmoud Farfoura Sensors.2025; 25(22): 7100. CrossRef
Botulinum Toxin for Axial Postural Abnormalities in Parkinson’s Disease: A Systematic Review Marialuisa Gandolfi, Carlo Alberto Artusi, Gabriele Imbalzano, Serena Camozzi, Mauro Crestani, Leonardo Lopiano, Michele Tinazzi, Christian Geroin Toxins.2024; 16(5): 228. CrossRef
Three‐Dimensional Mesh Recovery from Common 2‐Dimensional Pictures for Automated Assessment of Body Posture in Camptocormia Robin Wolke, Olga Gavriliuc, Oliver Granert, Günther Deuschl, Nils G. Margraf Movement Disorders Clinical Practice.2023; 10(3): 472. CrossRef
Assessment of Axial Postural Abnormalities in Parkinsonism: Automatic Picture Analysis Software Carlo Alberto Artusi, Christian Geroin, Gabriele Imbalzano, Serena Camozzi, Stefano Aldegheri, Leonardo Lopiano, Michele Tinazzi, Nicola Bombieri Movement Disorders Clinical Practice.2023; 10(4): 636. CrossRef
Camera- and Viewpoint-Agnostic Evaluation of Axial Postural Abnormalities in People with Parkinson’s Disease through Augmented Human Pose Estimation Stefano Aldegheri, Carlo Alberto Artusi, Serena Camozzi, Roberto Di Marco, Christian Geroin, Gabriele Imbalzano, Leonardo Lopiano, Michele Tinazzi, Nicola Bombieri Sensors.2023; 23(6): 3193. CrossRef
Objective To assess nocturnal hypokinesia using the Korean version of the Nocturnal Hypokinesia Questionnaire (NHQ-K) in Parkinson’s disease (PD) patients across disease stages.
Methods We developed the NHQ-K and performed questionnaire-based interviews with 108 PD patients from three referral hospitals. Clinical associations of nocturnal hypokinesia and its impact on health-related quality of life (HRQoL) were also analyzed.
Results The NHQ-K showed acceptable internal consistency (0.83) and interrater reliability (0.95). Nocturnal hypokinesia significantly affected HRQoL in PD patients at both the early and advanced stages (adjusted p < 0.001). Increased severity of nocturnal hypokinesia was associated with dyskinesias, off-period disability, apathy, and anxious mood in PD patients (adjusted p < 0.01) after controlling for disease severity and medication dose.
Conclusion The NHQ-K is useful for screening nocturnal hypokinesia in PD patients. Given the high impact of nocturnal hypokinesia on HRQoL, comprehensive management of nocturnal disability is needed for PD patients.
Citations
Citations to this article as recorded by
Telerehabilitation for the treatment of nocturnal hypokinesia in people with Parkinson’s disease: a pilot study Edoardo Bianchini, Francesco Bianchini, Pietro Lombardo, Silvia Galli, Flavia D’Audino, Marika Alborghetti, Domiziana Rinaldi Neurological Sciences.2026;[Epub] CrossRef
Opicapone for the Treatment of Nocturnal Hypokinesia in Patients With Parkinson’s Disease: An Open-Label Pilot Clinical Trial Chaewon Shin, Jong-Min Kim Journal of Movement Disorders.2026; 19(1): 81. CrossRef
Deep profiling of nocturnal hypokinesia in multiple system atrophy and its clinical implications Jongmok Ha, Suin Lee, Yoonha Hwang, Jinyoung Youn, Jin Whan Cho, Eun Yeon Joo Sleep Medicine.2025; 131: 106516. CrossRef
Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs Evita Papathoma, Panagiota Tsitsi, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Tiago A. Mestre, Alvaro Sanchez Ferro, Alberto J. Espay, Michelle H.S. Tosin, Matej Movement Disorders Clinical Practice.2025;[Epub] CrossRef
Technological evaluation of strategies to get out of bed by people with Parkinson's disease: Insights from multisite wearable sensors Jirada Sringean, Chusak Thanawattano, Roongroj Bhidayasiri Frontiers in Medical Technology.2022;[Epub] CrossRef
F-box only protein 7 (FBXO7) is a rare monogenic cause of hereditary Parkinson’s disease (PD) with an autosomal recessive mode of inheritance and a broad spectrum of clinical manifestations. Here, we report a de novo PD patient with onset at the age of 28 with novel compound heterozygous variants in the FBXO7 gene (c.1162C>T, p.Gln388X; c.80G>A, p.Arg27His). The clinical features of the patient were problematic impulse control disorder behaviors and pyromania, and pyramidal signs were negative. We describe the novel pathogenic variants of the FBXO7 gene with detailed clinical pictures to report the expanding genotypes and phenotypes of FBXO7-associated parkinsonism.
Citations
Citations to this article as recorded by
Mitochondrial Dysfunction in Genetic and Non-Genetic Parkinson’s Disease Martina Lucchesi, Letizia Biso, Marco Bonaso, Biancamaria Longoni, Bianca Buchignani, Roberta Battini, Filippo Maria Santorelli, Stefano Doccini, Marco Scarselli International Journal of Molecular Sciences.2025; 26(9): 4451. CrossRef
Global prevalence and incidence of Young Onset Parkinson’s disease: A systematic review and meta-analysis Fardin Nabizadeh, Homa Seyedmirzaei, Nazanin Rafiei, Seyedeh Maryam Vafaei, Dorsa Shekouh, Ehsan Mehrtabar, Ehsan Mirzaaghazadeh, Zahra Mirzaasgari Journal of Clinical Neuroscience.2024; 125: 59. CrossRef
Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co‐regulate proteasomes and mitochondria Sara Al Rawi, Lorna Simpson, Guðrún Agnarsdóttir, Neil Q. McDonald, Veronika Chernuha, Orly Elpeleg, Massimo Zeviani, Roger A. Barker, Ronen Spiegel, Heike Laman The FEBS Journal.2024; 291(12): 2565. CrossRef
Loss of the parkinsonism‐associated protein FBXO7 in glutamatergic forebrain neurons in mice leads to abnormal motor behavior and synaptic defects Jingbo Wang, Sabitha Joseph, Siv Vingill, Ekrem Dere, Lars Tatenhorst, Anja Ronnenberg, Paul Lingor, Christian Preisinger, Hannelore Ehrenreich, Jörg B. Schulz, Judith Stegmüller Journal of Neurochemistry.2023; 167(2): 296. CrossRef
Nearly Abolished Dopamine Transporter Uptake in a Patient With a Novel FBXO7 Mutation Eun Young Kim, Seon Young Kim, Youngduk Seo, Chaewon Shin Journal of Movement Disorders.2022; 15(3): 269. CrossRef
Adult-onset Niemann–Pick disease type C: A diagnostic and therapeutic odyssey of a rare condition Zeynep Ünlütürk, Eylem Teke Journal of Neurosciences in Rural Practice.2025; 16: 644. CrossRef
Lysosomal storage disorders identified in adult population from India: Experience of a tertiary genetic centre and review of literature Jayesh Sheth, Aadhira Nair, Riddhi Bhavsar, Koumudi Godbole, Chaitanya Datar, Sheela Nampoothiri, Inusha Panigrahi, Heli Shah, Shruti Bajaj, Naresh Tayade, Naveen Bhardwaj, Harsh Sheth JIMD Reports.2024; 65(2): 85. CrossRef
Genetic and phenotypic variability in adult patients with Niemann Pick type C from Serbia: single-center experience Nikola Kresojević, Valerija Dobričić, Milica Ječmenica Lukić, Aleksandra Tomić, Igor Petrović, Nataša Dragašević, Ivana Perović, Ana Marjanović, Marija Branković, Milena Janković, Ivana Novaković, Marina Svetel, Vladimir S. Kostić Journal of Neurology.2022; 269(6): 3167. CrossRef
Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life Melanie Wu, Rita Ceponiene, Ece Bayram, Irene Litvan Movement Disorders Clinical Practice.2020; 7(8): 961. CrossRef
Morphological differences between the two major subtypes of multiple system atrophy with cognitive impairment Kurt A. Jellinger Parkinsonism & Related Disorders.2023; 107: 105273. CrossRef
Neuropathological findings in multiple system atrophy with cognitive impairment Kurt A. Jellinger Journal of Neural Transmission.2020; 127(7): 1031. CrossRef
α-Synuclein and tau deposition in the central nervous system is responsible for various parkinsonian syndromes, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Emerging evidence has suggested that pathologic α-synuclein and tau are transmitted from cell to cell and further accelerate the aggregation of pathologic proteins in neighboring cells. Furthermore, extracellular pathologic proteins have also been reported to provoke inflammatory responses that lead to neurodegeneration. Therefore, immunotherapies targeting extracellular α-synuclein and tau have been proposed as potential disease-modifying strategies. In this review, we summarize completed phase I trials and ongoing phase II trials of immunotherapies against α-synuclein and tau and further discuss concerns and hurdles to overcome in the future.
Citations
Citations to this article as recorded by
A Panoramic View on Neurodegeneration, Its Connection with Microbiota and Its Therapeutics Tejas Ganatra, Pravin Tirgar International Journal of Scientific Research in Science and Technology.2026; 13(1): 01. CrossRef
The Inflammatory Mechanism of Parkinson’s Disease: Gut Microbiota Metabolites Affect the Development of the Disease Through the Gut–Brain Axis Ai Gao, Jiaqi Lv, Yanwei Su Brain Sciences.2025; 15(2): 159. CrossRef
Label-free electrochemical immunosensor for the accurate detection of α-synuclein based on Au/SiO2/Si electrode Nasrin Siraj Lopa, Mohammad Karbalaei Akbari, Yanbin Cui, Serge Zhuiykov Journal of Industrial and Engineering Chemistry.2025; 150: 548. CrossRef
Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials Xiaoni Zhan, Gehua Wen, Xu Wu, Jia-Yi Li Translational Neurodegeneration.2025;[Epub] CrossRef
Modeling neuroimmune dynamics in neurodegeneration: A nonlinear ODE framework for stability and transition analysis Faisal Sultan, Muhammad Shoaib Ishaq, Taofeek O. Alade, Muhammad Sohail, Gokul K. C. AIP Advances.2025;[Epub] CrossRef
Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration Wen Li, Jia-Yi Li Translational Neurodegeneration.2024;[Epub] CrossRef
Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance Dnyandev G. Gadhave, Vrashabh V. Sugandhi, Saurav Kumar Jha, Sopan N. Nangare, Gaurav Gupta, Sachin Kumar Singh, Kamal Dua, Hyunah Cho, Philip M. Hansbro, Keshav Raj Paudel Ageing Research Reviews.2024; 99: 102357. CrossRef
Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy Salma M. Al-Tuwairqi, Asma A. Badrah AIMS Mathematics.2023; 8(1): 1800. CrossRef
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy Winston T. Chu, Jesse Hall, Anjela Gurrala, Alexander Becsey, Shreya Raman, Michael S. Okun, Catherine T. Flores, Benoit I. Giasson, David E. Vaillancourt, Vinata Vedam-Mai ACS Chemical Neuroscience.2023; 14(2): 235. CrossRef
Direct digital sensing of protein biomarkers in solution Georg Krainer, Kadi L. Saar, William E. Arter, Timothy J. Welsh, Magdalena A. Czekalska, Raphaël P. B. Jacquat, Quentin Peter, Walther C. Traberg, Arvind Pujari, Akhila K. Jayaram, Pavankumar Challa, Christopher G. Taylor, Lize-Mari van der Linden, Titus Nature Communications.2023;[Epub] CrossRef
Inflammation in multiple system atrophy Marta Leńska-Mieciek, Natalia Madetko-Alster, Piotr Alster, Leszek Królicki, Urszula Fiszer, Dariusz Koziorowski Frontiers in Immunology.2023;[Epub] CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare Acta Neuropathologica.2022; 143(1): 55. CrossRef
RETRACTED ARTICLE: Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan, npj Vaccines.2022;[Epub] CrossRef
Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim Journal of Movement Disorders.2022; 15(1): 1. CrossRef
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies Dhanya Vijayakumar, Joseph Jankovic CNS Drugs.2022; 36(4): 327. CrossRef
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases Urmi Sengupta, Rakez Kayed Progress in Neurobiology.2022; 214: 102270. CrossRef
Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach Asma Badrah, Salma Al-Tuwairqi Physical Biology.2022; 19(5): 056004. CrossRef
Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease Le Zhao, Dan Li, Xiaofen Qi, Kaifang Guan, Haoran Chen, Rongchun Wang, Ying Ma Food & Function.2022; 13(21): 10851. CrossRef
Harnessing the immune system for the treatment of Parkinson’s disease Vinata Vedam-Mai Brain Research.2021; 1758: 147308. CrossRef
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease Katja Badanjak, Sonja Fixemer, Semra Smajić, Alexander Skupin, Anne Grünewald International Journal of Molecular Sciences.2021; 22(9): 4676. CrossRef
Viral alpha-synuclein knockdown prevents spreading synucleinopathy Sindhu Menon, Rikke H Kofoed, Fadl Nabbouh, Kristiana Xhima, Yasmeen Al-Fahoum, Tammy Langman, Howard T J Mount, Lamya S Shihabuddin, S Pablo Sardi, Paul E Fraser, Joel C Watts, Isabelle Aubert, Anurag Tandon Brain Communications.2021;[Epub] CrossRef
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah Neurotherapeutics.2020; 17(3): 935. CrossRef
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease Kyu-Young Sim, Kyeong Chan Im, Sung-Gyoo Park International Journal of Molecular Sciences.2020; 21(15): 5295. CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll Alzheimer's Research & Therapy.2020;[Epub] CrossRef
New Insights Into Drug Discovery Targeting Tau Protein Yoshiyuki Soeda, Akihiko Takashima Frontiers in Molecular Neuroscience.2020;[Epub] CrossRef
The Clinical Spectrum of ANO3—Report of a New Family and Literature Review Marco Percetti, Michela Zini, Paola Soliveri, Filippo Cogiamanian, Mariarosa Ferrara, Eva Orunesu, Alessandra Ranghetti, Carlo Ferrarese, Gianni Pezzoli, Barbara Garavaglia, Ioannis Ugo Isaias, Giorgio Sacilotto Movement Disorders Clinical Practice.2024; 11(3): 289. CrossRef
The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis Harini Sarva, Federico Rodriguez-Porcel, Francisco Rivera, Claudio Daniel Gonzalez, Samantha Barkan, Susmit Tripathi, Emilia Gatto, Pedro Garcia Ruiz Journal of the Neurological Sciences.2024; 459: 122970. CrossRef
A novel ANO3 variant in two siblings with different phenotypes Marcello Esposito, Assunta Trinchillo, Francesca Piceci-Sparascio, Maria Cecilia D'Asdia, Federica Consoli, Alessandro De Luca Parkinsonism & Related Disorders.2023; 111: 105413. CrossRef
DBS-Evoked Pallidal Activity Correlates with Clinical Improvement in a Patient with ANO3-Related Dystonia Aditya Boddu, Adam Bashir, Mohammad Awad, Barton Guthrie, Harrison Walker SSRN Electronic Journal.2023;[Epub] CrossRef
Deep Brain Stimulation in Dystonia: Disentangling Heterogeneity Alberto Albanese Movement Disorders Clinical Practice.2021; 8(1): 6. CrossRef
Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome Stephen Tisch, Kishore Raj Kumar Frontiers in Neurology.2021;[Epub] CrossRef
The expanding clinical and genetic spectrum of ANO3 dystonia Li-Ting Jiang, Li-Xi Li, Ying Liu, Xiao-Long Zhang, You-Gui Pan, Lin Wang, Xin-Hua Wan, Ling-Jing Jin Neuroscience Letters.2021; 746: 135590. CrossRef
Huntington disease-like phenotype in a patient with ANO3 mutation Shahedah Koya Kutty, Eoin Mulroy, Francesca Magrinelli, Giulia Di Lazzaro, Anna Latorre, Kailash P. Bhatia Parkinsonism & Related Disorders.2021; 90: 120. CrossRef
Arching deep brain stimulation in dystonia types Han-Joon Kim, Beomseok Jeon Journal of Neural Transmission.2021; 128(4): 539. CrossRef
Objective It is unclear whether the decline in dopamine transporters (DAT) differs among idiopathic rapid eye movement sleep behavior disorder (iRBD) patients with different levels of olfactory impairment. This study aimed to characterize DAT changes in relation to nonmotor features in iRBD patients by olfactory loss.
Methods This prospective cohort study consisted of three age-matched groups: 30 polysomnography-confirmed iRBD patients, 30 drug-naïve Parkinson’s disease patients, and 19 healthy controls without olfactory impairment. The iRBD group was divided into two groups based on olfactory testing results. Participants were evaluated for reported prodromal markers and then underwent 18F-FP-CIT positron emission tomography and 3T MRI. Tracer uptakes were analyzed in the caudate, anterior and posterior putamen, substantia nigra, and raphe nuclei.
Results Olfactory impairment was defined in 38.5% of iRBD patients. Mild parkinsonian signs and cognitive functions were not different between the two iRBD subgroups; however, additional prodromal features, constipation, and urinary and sexual dysfunctions were found in iRBD patients with olfactory impairment but not in those without. Tracer uptake showed significant group differences in all brain regions, except the raphe nuclei. The iRBD patients with olfactory impairment had uptake reductions in the anterior and posterior putamen, caudate, and substantia nigra (p < 0.016 in all, adjusted for age), which ranged from 0.6 to 0.8 of age-normative values. In contrast, those without olfactory impairment had insignificant changes in all regions ranging above 0.8.
Conclusion There was a clear distinction in DAT loss and nonmotor profiles by olfactory status in iRBD.
Citations
Citations to this article as recorded by
Blood microbiome signatures in the REM sleep behavior disorder–Lewy body disease continuum Ryul Kim, Sujin Oh, Kyung Ah Woo, Cheol Min Shin, Kyoung Un Park, Jee-Young Lee Journal of Neural Transmission.2025; 132(8): 1143. CrossRef
Longitudinal Trajectory of Multimodal Markers in a Patient with Isolated REM Sleep Behavior Disorder Seohee Choi, Ryul Kim, Kyung Ah Woo, Jung Hwan Shin, Eun Jin Yoon, Heejung Kim, Yu Kyeong Kim, Jee‐Young Lee Movement Disorders.2025; 40(12): 2842. CrossRef
Cholinergic basal forebrain degeneration in isolated REM sleep behaviour disorder Ryul Kim, Bora Jin, Heejung Kim, Kyung Ah Woo, Eun Jin Yoon, Seoyeon Kim, Jung Hwan Shin, Hyunwoo Nam, Yu Kyeong Kim, Beomseok Jeon, Jee-Young Lee Brain.2025; 148(11): 4084. CrossRef
Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum Beatrice Orso, Pietro Mattioli, Francesco Famà, Federico Massa, Andrea Brugnolo, Nicola Giovanni Girtler, Mattia Losa, Michele Terzaghi, Stefano Raffa, Luca Sofia, Silvia Morbelli, Matteo Pardini, Dario Arnaldi Neurology.2025;[Epub] CrossRef
Neuropsychological Changes in Isolated REM Sleep Behavior Disorder: A Systematic Review and Meta-analysis of Cross-sectional and Longitudinal Studies Caterina Leitner, Giada D’Este, Laura Verga, Shady Rahayel, Samantha Mombelli, Marco Sforza, Francesca Casoni, Marco Zucconi, Luigi Ferini-Strambi, Andrea Galbiati Neuropsychology Review.2024; 34(1): 41. CrossRef
Dopamine transporter positron emission tomography in patients with Alzheimer’s disease with Lewy body disease features Sungwoo Kang, Seun Jeon, Young-gun Lee, Byoung Seok Ye Neurobiology of Aging.2024; 134: 57. CrossRef
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET Changhwan Sung, Seung Jun Oh, Jae Seung Kim Nuclear Medicine and Molecular Imaging.2024; 58(4): 185. CrossRef
Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort Beatrice Orso, Pietro Mattioli, Eun-Jin Yoon, Yu Kyeong Kim, Heejung Kim, Jung Hwan Shin, Ryul Kim, Claudio Liguori, Francesco Famà, Andrea Donniaquio, Federico Massa, David Vállez García, Sanne K. Meles, Klaus L. Leenders, Agostino Chiaravalloti, Matteo Neurological Sciences.2023; 44(9): 3161. CrossRef
Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder Don Gueu Park, Ju Yeong Kim, Min Seung Kim, Mi Hee Kim, Young-Sil An, Jaerak Chang, Jung Han Yoon Journal of Neurology.2023; 270(9): 4393. CrossRef
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study Jung Hwan Shin, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyunwoo Nam, Beomseok Jeon, Jee-Young Lee Translational Neurodegeneration.2023;[Epub] CrossRef
Brain olfactory‐related atrophy in isolated rapid eye movement sleep behavior disorder Kyung Ah Woo, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Hyunwoo Nam, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee Annals of Clinical and Translational Neurology.2023; 10(12): 2192. CrossRef
Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease Kyung Ah Woo, Joo Hong Joun, Eun Jin Yoon, Chan Young Lee, Beomseok Jeon, Yu Kyeong Kim, Jee‐Young Lee Movement Disorders.2023; 38(12): 2291. CrossRef
Altered cerebral perfusion and microstructure in advanced Parkinson’s disease and their associations with clinical features Zhaoxi Liu, Yiwei Zhang, Han Wang, Dan Xu, Hui You, Zhentao Zuo, Feng Feng Neurological Research.2022; 44(1): 47. CrossRef
Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Systematic Review Rafail Matzaras, Kuangyu Shi, Artemios Artemiadis, Panagiotis Zis, Georgios Hadjigeorgiou, Axel Rominger, Claudio L.A. Bassetti, Panagiotis Bargiotas Journal of Parkinson's Disease.2022; 12(1): 69. CrossRef
Odor Identification by Parkinson’s Disease Patients Tested by Using Sniffin’ Sticks versus Natural Spices Florence Baert, Geertrui Vlaemynck, Jarissa Maselyne, Christophe Matthys, Seyed-Mohammad Fereshtehnejad Parkinson's Disease.2022;[Epub] CrossRef
Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease Ryul Kim, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyun Woo Nam, Beomseok Jeon, Jee‐Young Lee Movement Disorders.2022; 37(10): 2099. CrossRef
Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder‐Related Metabolic Pattern Expression Ryul Kim, Jee‐Young Lee, Yu Kyeong Kim, Heejung Kim, Eun Jin Yoon, Jung Hwan Shin, Dallah Yoo, Hyunwoo Nam, Beomseok Jeon Movement Disorders.2021; 36(8): 1889. CrossRef
Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Eun Jin Yoon, Heejung Kim, Hyunwoo Nam, Beomseok Jeon Neurology.2021;[Epub] CrossRef
Retina Thickness as a Marker of Neurodegeneration in Prodromal Lewy Body Disease Jee‐Young Lee, Jeeyun Ahn, Sohee Oh, Joo Young Shin, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon Movement Disorders.2020; 35(2): 349. CrossRef
Serum TNF-α and neurodegeneration in isolated REM sleep behavior disorder Ryul Kim, Jee-Young Lee, Han-Joon Kim, Yu Kyeong Kim, Hyunwoo Nam, Beomseok Jeon Parkinsonism & Related Disorders.2020; 81: 1. CrossRef
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder Jung Hwan Shin, Jee-Young Lee, Yu-Kyeong Kim, Sung-A Shin, Heejung Kim, Hyunwoo Nam, Beomseok Jeon Neurology.2020;[Epub] CrossRef
The current body of literature contains 5 reports of myotonic dystrophy (DM) with parkinsonism: 4 reports of DM type 2 and 1 report of clinically suspected DM type 1. To date, there have been no genetically proven cases of DM type 1 with parkinsonism. Here, we report the first case of genetically proven DM type 1 and parkinsonism that developed ahead of muscle symptoms with bilateral putaminal, presynaptic dopaminergic deficits on imaging. A 54-year-old female patient presented with bradykinesia, axial and bilateral limb rigidity, stooped posture, and hypomimia, which did not respond to levodopa. At age 56, she developed neck flexion weakness. Examination showed bilateral facial weakness, percussion and grip myotonia, and electromyography confirmed myotonic discharges. A genetic study of DM type 1 showed a DMPK mutation. At age 58, gait freezing, postural instability, and frequent falling developed and did not respond to increasing doses of levodopa. At age 59, the patient died from asphyxia.
Objective
Musculoskeletal problems are more common in patients with Parkinson’s disease (PD) than in normal elderly, but the impact of musculoskeletal problems on health-related quality of life (HRQoL) in patients with PD is unknown.
Methods
Four hundred consecutive patients with PD were enrolled for the evaluation of musculoskeletal problems and HRQoL. HRQoL was assessed by the 36-Item Short Form Health Survey, which comprised physical health and mental health.
Results
Of the total patients, 265 patients had musculoskeletal problems, and 135 patients did not have musculoskeletal problems. Patients with musculoskeletal problems reported lower levels of HRQoL in terms of physical health than did patients without musculoskeletal problems (p < 0.05). In women, all components of physical health were lower in patients with musculoskeletal problems than in patients without musculoskeletal problems (p < 0.05). Meanwhile, in men, only the bodily pain score of physical health was lower in patients with musculoskeletal problems than in patients without musculoskeletal problems. Mental health and physical health were negatively correlated with depression, Unified Parkinson’s Disease Rating Scale I & II scores, and pain severity from musculoskeletal problems, in that order (p < 0.01 for all).
Conclusion
These results suggest that musculoskeletal problems in patients with PD affect HRQoL significantly, mainly in terms of physical health rather than mental health and especially in women rather than men. Musculoskeletal problems should not be overlooked in the care of patients with PD.
Citations
Citations to this article as recorded by
Characteristics of pain symptoms in Parkinson’s disease Dung Thi Hoang, Frank Xing, Daniel Truong Clinical Parkinsonism & Related Disorders.2025; 13: 100404. CrossRef
Pain syndrome in Parkinson’s disease: unresolved issues of classification, park-pain, and the “blind spot” in diagnosis Elena V. Smirnova, Natalia G. Zhukova L.O. Badalyan Neurological Journal.2025; 6(3): 172. CrossRef
Assessments scales for the evaluation of health-related quality of life in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a systematic review Maria Lucia Maiuolo, Roberto Giorgini, Maria Grazia Vaccaro, Alessio Facchin, Andrea Quattrone, Aldo Quattrone Frontiers in Psychology.2024;[Epub] CrossRef
Total knee arthroplasty in patients with Parkinson’s disease: A systematic review and meta-analysis protocol Guangchen Sun, Hui Yu, Jun Cui, Ming Li, Yuefang Ru Medicine.2022; 101(52): e32315. CrossRef
Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana Dominic A. Alaazi, Devidas Menon, Tania Stafinski, Stephen Hodgins, Gian Jhangri Social Science & Medicine.2021; 270: 113659. CrossRef
The Efficiency of Spa Rehabilitation in Chronic Ischemic Stroke Patients—Preliminary Reports Bogumiła Pniak, Justyna Leszczak, Jadwiga Kurczab, Aleksandra Krzemińska, Joanna Pięta, Agnieszka Plis, Ewelina Czenczek-Lewandowska, Agnieszka Guzik Brain Sciences.2021; 11(4): 501. CrossRef
Sex-specific effects of subthalamic nucleus stimulation on pain in Parkinson’s disease Olga Khazen, Marisa DiMarzio, Kelsey Platanitis, Heather C. Grimaudo, Maria Hancu, Miriam M. Shao, Michael D. Staudt, Lucy Maguire, Vishad V. Sukul, Jennifer Durphy, Era K. Hanspal, Octavian Adam, Eric Molho, Julie G. Pilitsis Journal of Neurosurgery.2021; 135(2): 629. CrossRef
An overview of pain in Parkinson's disease Yi-Cheng Tai, Chin-Hsien Lin Clinical Parkinsonism & Related Disorders.2020; 2: 1. CrossRef
Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists Ji-Hyun Choi, Jong-Min Kim, Hee Kyung Yang, Hyo-Jung Lee, Cheol Min Shin, Seong Jin Jeong, Won-Seok Kim, Ji Won Han, In-Young Yoon, Yoo Sung Song, Yun Jung Bae Journal of Korean Medical Science.2020;[Epub] CrossRef
Parkinson's Disease Is Associated with Increased Complications, Readmission Rates, and Costs of Care after Total Hip Arthroplasty: A Matched-Cohort Analysis Simon Katz, Kevin B. Marchand, Rushabh M. Vakharia, Hiba Anis, Nipun Sodhi, Nicolas S. Piuzzi, Michael A. Mont, Martin W. Roche The Journal of Hip Surgery.2020; 4(03): 149. CrossRef
Chronic Pain Treatment Strategies in Parkinson’s Disease Amber Edinoff, Niro Sathivadivel, Timothy McBride, Allyson Parker, Chikezie Okeagu, Alan D. Kaye, Adam M. Kaye, Jessica S. Kaye, Rachel J. Kaye, Meeta M. Sheth, Omar Viswanath, Ivan Urits Neurology International.2020; 12(3): 61. CrossRef
Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinson's disease Ryul Kim, Dallah Yoo, Ji-Hyun Choi, Jung Hwan Shin, Sangmin Park, Han-Joon Kim, Sun Ha Paek, Beomseok Jeon Parkinsonism & Related Disorders.2019; 68: 73. CrossRef
Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon
J Mov Disord. 2018;11(2):65-71. Published online May 30, 2018
Objective
We examined whether amantadine can prevent the development of dyskinesia.
Methods
Patients with drug-naïve Parkinson’s disease (PD), younger than 70 years of age and in the early stage of PD (Hoehn and Yahr scale < 3), were recruited from April 2011 to December 2014. The exclusion criteria included the previous use of antiparkinsonian medication, the presence of dyskinesia, significant psychological disorders, and previous history of a hypersensitivity reaction. Patients were consecutively assigned to one of 3 treatment groups in an open label fashion: Group A-1, amantadine first and then levodopa when needed; Group A-2, amantadine first, dopamine agonist when needed, and then levodopa; and Group B, dopamine agonist first and then levodopa when needed. The primary endpoint was the development of dyskinesia, which was analyzed by the Kaplan-Meier survival rate.
Results
A total of 80 patients were enrolled: Group A-1 (n = 27), Group A-2 (n = 27), and Group B (n = 26). Twenty-four patients were excluded from the analysis due to the following: withdrawal of amantadine or dopamine agonist (n = 9), alternative diagnosis (n = 2), withdrawal of consent (n = 1), and breach in the protocol (n = 12). After exclusion, 5 of the 56 (8.93%) patients developed dyskinesia. Patients in Group A-1 and A-2 tended to develop dyskinesia less often than those in Group B (cumulative survival rates of 0.933, 0.929, and 0.700 for A-1, A-2, and B, respectively; p = 0.453).
Conclusion
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.
Citations
Citations to this article as recorded by
Amantadine: a first option for symptomatic relief in young-onset Parkinson's disease? Hyeyoung Park, Bastiaan R. Bloem, Beomseok Jeon Parkinsonism & Related Disorders.2026; 144: 108215. CrossRef
Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization Tao Wang, Jiaquan Geng, Xi Zeng, Ruijiang Han, Young Eun Huh, Jiajie Peng npj Parkinson's Disease.2024;[Epub] CrossRef
Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon Journal of Movement Disorders.2023; 16(2): 224. CrossRef
Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung J. Bedarf, I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner DGNeurologie.2023; 6(6): 504. CrossRef
Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(1): 17. CrossRef
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat Imane Frouni, Woojin Kang, Dominique Bédard, Sébastien Belliveau, Cynthia Kwan, Shadi Hadj-Youssef, Élodie Bourgeois-Cayer, Leanne Ohlund, Lekha Sleno, Adjia Hamadjida, Philippe Huot European Journal of Pharmacology.2022; 929: 175090. CrossRef
Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19 E.A. Katunina Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101. CrossRef
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef
Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang Journal of Neuroscience Research.2020; 98(1): 19. CrossRef
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji Expert Opinion on Emerging Drugs.2020; 25(2): 131. CrossRef
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD) Michelle Ann C. Sy, Hubert H. Fernandez Neurotherapeutics.2020; 17(4): 1331. CrossRef
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease Jing Liu, Fei Xu, Zhiyan Nie, Lei Shao Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold? Susan H. Fox, Jonathan M. Brotchie European Journal of Neuroscience.2019; 49(3): 399. CrossRef
Polypharmacy in Parkinson’s disease: risks and benefits with little evidence I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner Journal of Neural Transmission.2019; 126(7): 871. CrossRef
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot Neuropharmacology.2019; 158: 107725. CrossRef
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update Valentina Leta, Peter Jenner, K. Ray Chaudhuri, Angelo Antonini Expert Opinion on Drug Safety.2019; 18(12): 1203. CrossRef
Genetic updates on paroxysmal dyskinesias James Y. Liao, Philippe A. Salles, Umar A. Shuaib, Hubert H. Fernandez Journal of Neural Transmission.2021; 128(4): 447. CrossRef
A Japanese family with primary familial brain calcification presenting with paroxysmal kinesigenic dyskinesia - A comprehensive mutational analysis- Akihiko Mitsutake, Takashi Matsukawa, Kristine Joyce L. Porto, Tatsuya Sato, Junko Katsumata, Tomonari Seki, Risa Maekawa, Takuto Hideyama, Masaki Tanaka, Hiroyuki Ishiura, Tatsushi Toda, Shoji Tsuji, Yasushi Shiio Journal of the Neurological Sciences.2020; 418: 117091. CrossRef
Paroxysmal movement disorders – practical update on diagnosis and management Claudio M. De Gusmao, Laura Silveira-Moriyama Expert Review of Neurotherapeutics.2019; 19(9): 807. CrossRef
The study of exercise tests in paroxysmal kinesigenic dyskinesia Hai-Yan Zhou, Fei-Xia Zhan, Wo-Tu Tian, Chao Zhang, Yan Wang, Ze-Yu Zhu, Xiao-Li Liu, Yang-Qi Xu, Xing-Hua Luan, Xiao-Jun Huang, Sheng-Di Chen, Li Cao Clinical Neurophysiology.2018; 129(11): 2435. CrossRef
Objective
Two conversion tables between the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have recently been established for Parkinson’s disease (PD). This study aimed to validate them in Korean patients with PD and to evaluate whether they could be influenced by educational level.
Methods
A total of 391 patients with PD who undertook both the Korean MMSE and the Korean MoCA during the same session were retrospectively assessed. The mean, median, and root mean squared error (RMSE) of the difference between the true and converted MMSE scores and the intraclass correlation coefficient (ICC) were calculated according to educational level (6 or fewer years, 7–12 years, or 13 or more years).
Results
Both conversions had a median value of 0, with a small mean and RMSE of differences, and a high correlation between the true and converted MMSE scores. In the classification according to educational level, all groups had roughly similar values of the median, mean, RMSE, and ICC both within and between the conversions.
Conclusion
Our findings suggest that both MMSE-MoCA conversion tables are useful instruments for transforming MoCA scores into converted MMSE scores in Korean patients with PD, regardless of educational level. These will greatly enhance the utility of the existing cognitive data from the Korean PD population in clinical and research settings.
Citations
Citations to this article as recorded by
Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer’s disease Friederike Völter, Sebastian Eckenweber, Maximilian Scheifele, Florian Eckenweber, Fabian Hirsch, Nicolai Franzmeier, Annika Kreuzer, Maria Griessl, Anna Steward, Daniel Janowitz, Carla Palleis, Alexander Bernhardt, Jonathan Vöglein, Anna Stockbauer, Bori European Journal of Nuclear Medicine and Molecular Imaging.2025; 52(8): 2918. CrossRef
Effect of Sit-to-Stand Training with Leg Lead on Balance and Gait in Parkinson’s Disease Patients Hye-Jin Kim, Cheol-Jin Kang, Sung-Min Son The Journal of Korean Physical Therapy.2025; 37(4): 205. CrossRef
Heterogeneous factors influence social cognition across diverse settings in brain health and age-related diseases Sol Fittipaldi, Agustina Legaz, Marcelo Maito, Hernan Hernandez, Florencia Altschuler, Veronica Canziani, Sebastian Moguilner, Claire M. Gillan, Josefina Castillo, Patricia Lillo, Nilton Custodio, José Alberto Avila-Funes, Juan Felipe Cardona, Andrea Slac Nature Mental Health.2024; 2(1): 63. CrossRef
Application of machine learning models on predicting the length of hospital stay in fragility fracture patients Chun-Hei Lai, Prudence Kwan-Lam Mok, Wai-Wang Chau, Sheung-Wai Law BMC Medical Informatics and Decision Making.2024;[Epub] CrossRef
Gaze Scanning on Mid-Block Sidewalks by Pedestrians With Homonymous Hemianopia With or Without Spatial Neglect Shrinivas Pundlik, Matteo Tomasi, Kevin E. Houston, Ayush Kumar, Prerana Shivshanker, Alex R. Bowers, Eli Peli, Gang Luo Investigative Ophthalmology & Visual Science.2024; 65(8): 46. CrossRef
Effects of nonimmersive virtual reality using Wii-Fit exercises on balance and cognition in Parkinson disease: A meta-analysis Fouzia Hussain, Sumaira Farooqui, Amna Aamir Khan, Muhammad Usman Khan, Muhammad Abid Khan, Ahad Hasan Medicine.2024; 103(30): e38940. CrossRef
Association between elevated glycosylated hemoglobin and cognitive impairment in older Korean adults: 2009–2010 Ansan cohort of the Korean genome and epidemiology study Jung Sook Kim, Byung Chul Chun, Kyoungho Lee Frontiers in Public Health.2024;[Epub] CrossRef
Whole-Body and Segmental Phase Angles and Cognitive Function in the Older Korean Population: Cross-Sectional Analysis Jiaren Chen, Jong-Hwan Park, Chien-Yu Lin, Ting-Fu Lai, Du-Ri Kim, Myung-Jun Shin, Eunsoo Moon, Jung Mo Kang, Jong Won Lee, Yoon Jae Cho, Yung Liao, Tae Sik Goh, Jung Sub Lee JMIR Public Health and Surveillance.2024; 10: e63457. CrossRef
Gaze Scanning at Street Crossings by Pedestrians With Homonymous Hemianopia With and Without Hemispatial Neglect Shrinivas Pundlik, Matteo Tomasi, Kevin E. Houston, Ayush Kumar, Prerana Shivshanker, Alex R. Bowers, Eli Peli, Gang Luo Investigative Opthalmology & Visual Science.2023; 64(14): 26. CrossRef
Comparative study of two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive Impairment Yu-Yuan Huang, Shu-Xia Qian, Qiao-Bing Guan, Ke-Liang Chen, Qian-Hua Zhao, Jia-Hong Lu, Qi-Hao Guo Applied Neuropsychology: Adult.2021; 28(1): 88. CrossRef
Conversion between Mini‐Mental State Examination and Montreal Cognitive Assessment scores in older adults undergoing selective surgery using Rasch analysis Xiaoying Chen, Huangliang Wen, Jinni Wang, Yayan Yi, Jialan Wu, Xiaoyan Liao Journal of Advanced Nursing.2021; 77(2): 729. CrossRef
Converting from the Montreal Cognitive Assessment to the Mini-Mental State Examination-2 Hwabeen Yang, Daehyuk Yim, Moon Ho Park, Antony Bayer PLOS ONE.2021; 16(7): e0254055. CrossRef
Validation of Four Methods for Converting Scores on the Montreal Cognitive Assessment to Scores on the Mini-Mental State Examination-2 Sung Hoon Kang, Moon Ho Park Dementia and Neurocognitive Disorders.2021; 20(4): 41. CrossRef
Կոգնիտիվ վիճակի գնահատման Mini-Mental State Examination (MMSE) սանդղակի հայերեն տարբերակի ադապտացում և վալիդացում Մ.Ա. Իսայան, Հ.Ա. Հովակիմյան, Լ.Վ. Վարդանյան, Ս.Գ. Խաչատրյան, Զ.Դ. Թավադյան Armenian Journal of Health & Medical Sciences.2021; : 27. CrossRef
Determinant of Quality of Life in Patients with Chronic Cerebral Infarct Yujin Lee, Joon Sung Kim, Bo Young Hong, Jung Geun Park, Jae Wan Yoo, Kyoung Bo Lee, Tae-Woo Kim, Seong Hoon Lim Brain & Neurorehabilitation.2020;[Epub] CrossRef
Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease Jannik Florian Scheffels, Leon Fröhlich, Elke Kalbe, Josef Kessler Journal of the Neurological Sciences.2020; 412: 116735. CrossRef
Hand motor functions on the presence of red fluorescent dental biofilm in older community-dwelling Koreans Na-Ri Shin, Yeo-Jin Yi, Jun-Seon Choi Photodiagnosis and Photodynamic Therapy.2019; 28: 120. CrossRef
Is the modified Mann Assessment of Swallowing Ability useful for assessing dysphagia in patients with mild to moderate dementia? Eun Kyu Ji, Hae Hyun Wang, Sung June Jung, Kyoung Bo Lee, Joon Sung Kim, Bo Young Hong, Seong Hoon Lim Journal of Clinical Neuroscience.2019; 70: 169. CrossRef
The Changes for Strength of Oropharyngeal Muscles in Patients with Dementia and Dysphagia Eun Kyu Ji, Hae Hyun Wang, Sung June Jung, Kyoung Bo Lee, Joon Sung Kim, Bo Young Hong, Tae-Woo Kim, Seong Hoon Lim Brain & Neurorehabilitation.2019;[Epub] CrossRef
Konversionen von kognitiven Screenings J. F. Scheffels, H. Kräling, E. Kalbe, J. Kessler Der Nervenarzt.2018; 89(12): 1371. CrossRef
Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline Loic Carment, Abir Abdellatif, Carmelo Lafuente-Lafuente, Sylvie Pariel, Marc A. Maier, Joël Belmin, Påvel G. Lindberg Frontiers in Neurology.2018;[Epub] CrossRef
Validation of MoCA-MMSE Conversion Scales in Korean Patients with Cognitive Impairments Young Ik Jung, Eun Hye Jeong, Heejin Lee, Junghee Seo, Hyun-Jeong Yu, Jin Y. Hong, Mun Kyung Sunwoo Dementia and Neurocognitive Disorders.2018; 17(4): 148. CrossRef
Objective
Many people dealing with Parkinson’s disease (PD) turn to complementary and alternative medicine when searching for a cure or relief from symptoms. Acupuncture is widely used in the Korean PD population to alleviate symptoms and in hopes of curing the illness. However, acupuncture use for PD patients has only recently begun to be studied scientifically and is still considered an unproven treatment for PD. Therefore, there is an urgent need for acupuncture to be studied, validated and used for PD. Thus, our study’s aim is to examine how many acupuncture studies in PD are registered and reported in Korea.
Methods
The registries Clinicaltrials.gov and the Clinical Research Information Service (CRIS) and the search engine PubMed were searched to find relevant human clinical studies involving acupuncture therapy in PD patients. We examined the registration of trials, the posting and publication of results, and whether published articles were registered.
Results
In Clinicaltrials.gov, one completed trial was found with published results. In CRIS, one completed trial was found with published results. A total of 6 publications were found in our study: 2 articles were registered, but only 1 had the registered trial number listed in the article.
Conclusion
Acupuncture is popular among the PD population in Korea regardless of its unproven safety and efficacy. Despite the pressing need for clinical trials, the number of studies listed in the registries was small, and only a few publications were registered. More effort and rigor are needed to validate the efficacy and safety of acupuncture for PD.
Spinal myoclonus is a sudden, brief, and involuntary movement of segmental or propriospinal muscle groups. Spinal myoclonus has occasionally been reported in patients undergoing opioid therapy, but the pathophysiology of opioid-induced myoclonus has not been elucidated yet. Here, we present two patients with spinal segmental myoclonus secondary to ischemic and radiation myelopathy. Conventional medications did not help treat persistent myoclonus in both legs. Continuous intrathecal morphine infusion was implanted for pain control in one patient, which relieved spinal myoclonus entirely. This experience led to the application of this method with a second patient, leading to the same gratifying result. Spinal myoclonus reemerged as soon as the morphine pumps were off, which confirmed the therapeutic role of opioids. In contrast to the opioid-induced myoclonus, these cases show a benefit of opioids on spinal myoclonus, which could be explained by synaptic reorganization after pathologic insults in the spinal cord.
Citations
Citations to this article as recorded by
Cancer-related movement disorders: A scoping review and diagnostic approach Laura E Schroeder, Ethan Snow, Casandra Chen, Amy Addo, Nahid Mohammadzadeh, Lawrence Recht, Saud Alhusaini Neuro-Oncology Practice.2025; 12(6): 970. CrossRef
Spinal segmental myoclonus following spinal surgery Shrikant Pande, Kokcher Ang, May Win Myat, Shermyn Neo, Sivashankar Subramaniam British Journal of Neurosurgery.2023; 37(3): 393. CrossRef
Movement Disorders Associated With Radiotherapy and Surgical Procedures Bharath Kumar Surisetti, Shweta Prasad, Vikram Venkappayya Holla, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal Journal of Movement Disorders.2023; 16(1): 42. CrossRef
Myoclonus: An Electrophysiological Diagnosis Shabbir Hussain I. Merchant, Felipe Vial‐Undurraga, Giorgio Leodori, Jay A. van Gerpen, Mark Hallett Movement Disorders Clinical Practice.2020; 7(5): 489. CrossRef
Objective The survival of Huntington’s disease (HD) patients is reported to be 15–20 years. However, most studies on the survival of HD have been conducted in patients without genetic confirmation with the possible inclusion of non-HD patients, and all studies have been conducted in Western countries. The survival of patients with HD in East Asia, where its prevalence is 10–50-fold lower compared with Western populations, has not yet been reported.
Methods Forty-seven genetically confirmed Korean HD patients from independent families were included in this retrospective medical record review study.
Results The mean age at onset among the 47 patients was 46.1 ± 14.0 years. At the time of data collection, 25 patients had died, and these patients had a mean age at death of 57.8 ± 13.7 years. The Kaplan-Meier estimate of the median survival from onset in the 47 patients was 14.5 years (95% confidence interval: 12.3–16.6). None of the following factors were associated with the survival time in the univariate Cox regression analysis: gender, age at onset, normal CAG repeat size, mutant CAG repeat size, and the absence or presence of non-motor symptoms at onset.
Conclusion This is the first Asian study on survival in HD patients. Survival in Korean HD patients may be shorter than that reported for Western populations, or at least is in the lower range of expected survival. A larger longitudinal observation study is needed to confirm the results found in this study.
Citations
Citations to this article as recorded by
Analysis of HTT CAG repeat expansion among healthy individuals and patients with chorea in Korea Ryul Kim, Moon-Woo Seong, Bumjo Oh, Ho Seop Shin, Jee-Soo Lee, Sangmin Park, Mihee Jang, Beomseok Jeon, Han-Joon Kim, Jee-Young Lee Parkinsonism & Related Disorders.2024; 118: 105930. CrossRef
Clinical and Genetic Characteristics Associated With Survival Outcome in Late-Onset Huntington’s Disease in South Korea Yun Su Hwang, Sungyang Jo, Gu-Hwan Kim, Jee-Young Lee, Ho-Sung Ryu, Eungseok Oh, Seung-Hwan Lee, Young Seo Kim, Sun Ju Chung Journal of Clinical Neurology.2024; 20(4): 394. CrossRef
A Practical Guide for Clinical Approach to Patients With Huntington’s Disease in Korea Chaewon Shin, Ryul Kim, Dallah Yoo, Eungseok Oh, Jangsup Moon, Minkyeong Kim, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon Journal of Movement Disorders.2024; 17(2): 138. CrossRef
Evidence-Based Review on Symptomatic Management of Huntington’s Disease Jung Hwan Shin, Hui-Jun Yang, Jong Hyun Ahn, Sungyang Jo, Seok Jong Chung, Jee-Young Lee, Hyun Sook Kim, Manho Kim Journal of Movement Disorders.2024; 17(4): 369. CrossRef
Increased 10-Year Prevalence of Huntington’s Disease in South Korea: An Analysis of Medical Expenditure Through the National Healthcare System Chan Young Lee, Jun-soo Ro, Hyemin Jung, Manho Kim, Beomseok Jeon, Jee-Young Lee Journal of Clinical Neurology.2023; 19(2): 147. CrossRef
Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach Jinnie Ko, Hannah Furby, Xiaoye Ma, Jeffrey D. Long, Xiao-Yu Lu, Diana Slowiejko, Rita Gandhy Frontiers in Neurology.2023;[Epub] CrossRef
Survival in Huntington’s disease and other young‐onset dementias Samantha M. Loi, Paraskevi Tsoukra, Emily Sun, Zhibin Chen, Pierre Wibawa, Maria di Biase, Sarah Farrand, Dhamidhu Eratne, Wendy Kelso, Andrew Evans, Mark Walterfang, Dennis Velakoulis International Journal of Geriatric Psychiatry.2023;[Epub] CrossRef
Functional Intercellular Transmission of miHTT via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study Roberto D. V. S. Morais, Marina Sogorb-González, Citlali Bar, Nikki C. Timmer, M. Leontien Van der Bent, Morgane Wartel, Astrid Vallès Cells.2022; 11(17): 2748. CrossRef
Huntington's disease: Mortality and risk factors in an Australian cohort Emily Sun, Matthew Kang, Pierre Wibawa, Vivian Tsoukra, Zhibin Chen, Sarah Farrand, Dhamidhu Eratne, Wendy Kelso, Andrew Evans, Mark Walterfang, Dennis Velakoulis, Samantha M. Loi Journal of the Neurological Sciences.2022; 442: 120437. CrossRef
Huntington’s disease in Turkey: genetic counseling, clinical features, and outcome Yesim Sucullu Karadag, Busranur Erozan Cavdarli, Rabia Nazik Yuksel Neurological Research.2021; 43(5): 381. CrossRef
Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain Esther Vicente, Ainara Ruiz de Sabando, Fermín García, Itziar Gastón, Eva Ardanaz, María A. Ramos-Arroyo Orphanet Journal of Rare Diseases.2021;[Epub] CrossRef
Epidemiology of Huntington disease in Cyprus: A 20‐year retrospective study C.A. Demetriou, A. Heraclides, C. Salafori, G.A. Tanteles, K. Christodoulou, Y. Christou, E. Zamba‐Papanicolaou Clinical Genetics.2018; 93(3): 656. CrossRef
Population-specific genetic modification of Huntington's disease in Venezuela Michael J. Chao, Kyung-Hee Kim, Jun Wan Shin, Diane Lucente, Vanessa C. Wheeler, Hong Li, Jared C. Roach, Leroy Hood, Nancy S. Wexler, Laura B. Jardim, Peter Holmans, Lesley Jones, Michael Orth, Seung Kwak, Marcy E. MacDonald, James F. Gusella, Jong-Min L PLOS Genetics.2018; 14(5): e1007274. CrossRef